OBJECTIVE: HIV infection in sub-Saharan Africa increasingly occurs among people who inject drugs (PWID). Kenya is one of the first to implement a national needle and syringe program. Our study undertook a baseline assessment as part of evaluating needle and syringe program in a seek, test, treat, and retain approach. METHODS: Participants enrolled between May and December 2012 from 10 sites. Respondent-driven sampling was used to reach 1785 PWID for HIV-1 prevalence and viral load determination and survey data. RESULTS: Estimated HIV prevalence, adjusted for differential network size and recruitment relationships, was 14.5% in Nairobi (95% CI: 10.8 to 18.2) and 20.5% in the Coast region (95% CI: 17.3 to 23.6). Viral load (log10 transformed) in Nairobi ranged from 1.71 to 6.12 (median: 4.41; interquartile range: 3.51-4.94) and in the Coast from 1.71 to 5.88 (median: 4.01; interquartile range: 3.44-4.72). Using log10 viral load 2.6 as a threshold for HIV viral suppression, the percentage of HIV-infected participants with viral suppression was 4.2% in Nairobi and 4.6% in the Coast. Heroin was the most commonly injected drug in both regions, used by 93% of participants in the past month, typically injecting 2-3 times/day. Receptive needle/syringe sharing at last injection was more common in Nairobi (23%) than in the Coast (4%). Estimated incidence among new injectors was 2.5/100 person-years in Nairobi and 1.6/100 person-years in the Coast. CONCLUSIONS: The HIV epidemic is well established among PWID in both Nairobi and Coast regions. Public health scale implementation of combination HIV prevention has the potential to greatly limit the epidemic in this vulnerable and bridging population.
OBJECTIVE:HIV infection in sub-Saharan Africa increasingly occurs among people who inject drugs (PWID). Kenya is one of the first to implement a national needle and syringe program. Our study undertook a baseline assessment as part of evaluating needle and syringe program in a seek, test, treat, and retain approach. METHODS:Participants enrolled between May and December 2012 from 10 sites. Respondent-driven sampling was used to reach 1785 PWID for HIV-1 prevalence and viral load determination and survey data. RESULTS: Estimated HIV prevalence, adjusted for differential network size and recruitment relationships, was 14.5% in Nairobi (95% CI: 10.8 to 18.2) and 20.5% in the Coast region (95% CI: 17.3 to 23.6). Viral load (log10 transformed) in Nairobi ranged from 1.71 to 6.12 (median: 4.41; interquartile range: 3.51-4.94) and in the Coast from 1.71 to 5.88 (median: 4.01; interquartile range: 3.44-4.72). Using log10 viral load 2.6 as a threshold for HIV viral suppression, the percentage of HIV-infectedparticipants with viral suppression was 4.2% in Nairobi and 4.6% in the Coast. Heroin was the most commonly injected drug in both regions, used by 93% of participants in the past month, typically injecting 2-3 times/day. Receptive needle/syringe sharing at last injection was more common in Nairobi (23%) than in the Coast (4%). Estimated incidence among new injectors was 2.5/100 person-years in Nairobi and 1.6/100 person-years in the Coast. CONCLUSIONS: The HIV epidemic is well established among PWID in both Nairobi and Coast regions. Public health scale implementation of combination HIV prevention has the potential to greatly limit the epidemic in this vulnerable and bridging population.
Authors: Don C Des Jarlais; Ryan Kling; Theodore M Hammett; Doan Ngu; Wei Liu; Yi Chen; Kieu Thanh Binh; Patricia Friedmann Journal: AIDS Date: 2007-12 Impact factor: 4.177
Authors: Davies O Kimanga; Samuel Ogola; Mamo Umuro; Anne Ng'ang'a; Lucy Kimondo; Patrick Murithi; James Muttunga; Wanjiru Waruiru; Ibrahim Mohammed; Shahnaaz Sharrif; Kevin M De Cock; Andrea A Kim Journal: J Acquir Immune Defic Syndr Date: 2014-05-01 Impact factor: 3.731
Authors: Steffanie A Strathdee; Timothy B Hallett; Natalia Bobrova; Tim Rhodes; Robert Booth; Reychad Abdool; Catherine A Hankins Journal: Lancet Date: 2010-07-24 Impact factor: 79.321
Authors: R Scott McClelland; Barbra A Richardson; George H Wanje; Susan M Graham; Esther Mutunga; Norbert Peshu; James N Kiarie; Ann E Kurth; Walter Jaoko Journal: Sex Transm Dis Date: 2011-05 Impact factor: 2.830
Authors: Abu S Abdul-Quader; Jonathan Feelemyer; Shilpa Modi; Ellen S Stein; Alya Briceno; Salaam Semaan; Tara Horvath; Gail E Kennedy; Don C Des Jarlais Journal: AIDS Behav Date: 2013-11
Authors: Jean B Nachega; Nadia A Sam-Agudu; Lynne M Mofenson; Mauro Schechter; John W Mellors Journal: Clin Infect Dis Date: 2018-05-02 Impact factor: 9.079
Authors: Matthew J Akiyama; Charles M Cleland; John A Lizcano; Peter Cherutich; Ann E Kurth Journal: Lancet Infect Dis Date: 2019-09-17 Impact factor: 25.071
Authors: Jennifer L Syvertsen; Spala Ohaga; Kawango Agot; Margarita Dimova; Andy Guise; Tim Rhodes; Karla D Wagner Journal: Int J Drug Policy Date: 2016-01-08
Authors: Nyashadzaishe Mafirakureva; Jack Stone; Hannah Fraser; Yvonne Nzomukunda; Aron Maina; Angela W Thiong'o; Kibango Walter Kizito; Esther W K Mucara; C Inés González Diaz; Helgar Musyoki; Bernard Mundia; Peter Cherutich; Mercy Nyakowa; John Lizcano; Nok Chhun; Ann Kurth; Matthew J Akiyama; Wanjiru Waruiru; Parinita Bhattacharjee; Charles Cleland; Dmytro Donchuk; Niklas Luhmann; Anne Loarec; David Maman; Josephine Walker; Peter Vickerman Journal: Addiction Date: 2021-07-28 Impact factor: 6.526